Acadesine

DRUG2 trials

Sponsors

Advancell - Advanced In Vitro Cell Technologies, S.A., Merck Sharp & Dohme LLC

Conditions

Cardiopulmonary BypassCoronary Artery BypassLeukemia, B-Cell, ChronicMyocardial InfarctionStrokeVentricular Dysfunction, Left

Phase 1

Safety and Tolerability Open Label Dose Escalation Study of Acadesine in B-CLL Patients

CompletedNCT00559624

Advancell - Advanced In Vitro Cell Technologies, S.A.Leukemia, B-Cell, Chronic

Start: 2007-12-31End: 2010-12-31Target: 40Updated: 2011-05-10

Phase 3

The Effect Of Acadesine On Reducing Cardiovascular and Cerebrovascular Adverse Events In Coronary Artery Bypass Graft (CABG) Surgery (Study P05633 AM1)(TERMINATED)

TerminatedNCT00872001

Merck Sharp & Dohme LLCCardiopulmonary Bypass, Coronary Artery Bypass, Myocardial Infarction +2

Start: 2009-04-30End: 2010-10-31Updated: 2015-10-29

Related Papers

Effect of adenosine-regulating agent acadesine on morbidity and mortality associated with coronary artery bypass grafting: the RED-CABG randomized controlled trial.

2012-07-0143 citations